Kenvue Inc. $KVUE Shares Acquired by Aigen Investment Management LP

Key Points

• Aigen Investment Management LP increased its Kenvue stake by 58.5% in the fourth quarter, buying 66,052 additional shares and bringing its total to 179,042 shares worth about $3.09 million.
• Kenvue reported solid quarterly results, with EPS of $0.32 beating estimates and revenue of $3.91 billion topping expectations; revenue also rose 4.5% year over year.
• The stock and analyst outlook remain mixed: KVUE was up 0.3% to $18.13, offers a 4.6% dividend yield, and carries a consensus analyst rating of “Hold” with an average price target of $19.33.

Aigen Investment Management LP grew its stake in Kenvue Inc. (NYSE:KVUE - Free Report) by 58.5% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 179,042 shares of the company's stock after buying an additional 66,052 shares during the period. Kenvue accounts for 0.7% of Aigen Investment Management LP's investment portfolio, making the stock its 22nd largest holding. Aigen Investment Management LP's holdings in Kenvue were worth $3,088,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also modified their holdings of the company. Kestra Advisory Services LLC boosted its stake in Kenvue by 4.2% during the 4th quarter. Kestra Advisory Services LLC now owns 173,807 shares of the company's stock worth $2,998,000 after purchasing an additional 6,998 shares during the period. Transamerica Financial Advisors LLC boosted its stake in Kenvue by 80.4% during the 4th quarter. Transamerica Financial Advisors LLC now owns 11,083 shares of the company's stock worth $191,000 after purchasing an additional 4,939 shares during the period. Marshall Wace LLP boosted its stake in Kenvue by 560.2% during the 4th quarter. Marshall Wace LLP now owns 5,826,776 shares of the company's stock worth $100,512,000 after purchasing an additional 4,944,173 shares during the period. Quinn Opportunity Partners LLC boosted its stake in Kenvue by 1,172.3% during the 4th quarter. Quinn Opportunity Partners LLC now owns 1,507,627 shares of the company's stock worth $26,007,000 after purchasing an additional 1,389,127 shares during the period. Finally, Soros Fund Management LLC acquired a new stake in Kenvue during the 4th quarter worth $21,498,000. Institutional investors and hedge funds own 97.64% of the company's stock.

Kenvue Stock Up 0.3%

Shares of Kenvue stock opened at $18.13 on Friday. The company has a market cap of $34.80 billion, a P/E ratio of 21.32, a PEG ratio of 1.38 and a beta of 0.54. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.70 and a current ratio of 0.98. Kenvue Inc. has a one year low of $14.02 and a one year high of $22.87. The firm has a fifty day moving average of $17.43 and a two-hundred day moving average of $17.53.

Kenvue (NYSE:KVUE - Get Free Report) last announced its quarterly earnings data on Thursday, May 7th. The company reported $0.32 EPS for the quarter, topping analysts' consensus estimates of $0.27 by $0.05. The company had revenue of $3.91 billion during the quarter, compared to the consensus estimate of $3.84 billion. Kenvue had a net margin of 10.61% and a return on equity of 20.81%. Kenvue's quarterly revenue was up 4.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.24 EPS. On average, analysts forecast that Kenvue Inc. will post 1.16 earnings per share for the current year.

Kenvue Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, May 27th. Shareholders of record on Wednesday, May 13th were given a dividend of $0.2075 per share. The ex-dividend date was Wednesday, May 13th. This represents a $0.83 dividend on an annualized basis and a yield of 4.6%. Kenvue's dividend payout ratio is presently 97.65%.

Analysts Set New Price Targets

KVUE has been the subject of a number of recent research reports. Barclays decreased their price target on shares of Kenvue from $19.00 to $18.00 and set an "equal weight" rating for the company in a research note on Tuesday, April 14th. UBS Group decreased their price target on shares of Kenvue from $19.00 to $18.00 and set a "neutral" rating for the company in a research note on Tuesday, April 7th. Argus upgraded shares of Kenvue to a "hold" rating in a research note on Friday, March 6th. Weiss Ratings cut shares of Kenvue from a "hold (c)" rating to a "hold (c-)" rating in a research note on Friday, May 29th. Finally, Citigroup decreased their price target on shares of Kenvue from $20.00 to $19.00 and set a "neutral" rating for the company in a research note on Wednesday, April 15th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and twelve have given a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of "Hold" and an average price target of $19.33.

Insider Buying and Selling

In other Kenvue news, General Counsel Matthew Orlando sold 38,491 shares of the company's stock in a transaction on Friday, May 8th. The shares were sold at an average price of $17.66, for a total transaction of $679,751.06. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 1.59% of the company's stock.

Kenvue Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.